Valneva SE (VALN) Payables (2020 - 2026)
Valneva SE (VALN) posted Payables of $25.5 million for Q1 2026, down 10.63% sequentially from $28.6 million in Q4 2025, and down 12.81% YoY from $29.3 million in Q1 2025.
Analysis
Valneva SE (VALN) Payables (2020 - 2026) Analysis & Trends
Valneva SE has reported Payables for 7 years, with the latest figure at $25.5 million in Q1 2026.
- Quarterly Payables fell 12.81% year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.5 million (down 12.81% YoY) and the FY2025 annual result came in at $28.6 million, down 25.7% from the prior year.
- Payables eased to $25.5 million in Q1 2026 per VALN's latest filing, from $28.6 million in the prior quarter.
- Over five years, Payables peaked at $102.6 million in Q3 2023 and troughed at $23.9 million in Q2 2025.
- A 5-year average of $53.4 million and a median of $47.1 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2024: Payables gained 16.33% in 2023, then plunged 54.08% in 2024.
- Over 5 years, Payables stood at $54.1 million in 2022, then fell by 11.96% to $47.7 million in 2023, then fell by 20.37% to $38.0 million in 2024, then slipped by 24.75% to $28.6 million in 2025, then fell by 10.63% to $25.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $25.5 million, $28.6 million, and $35.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 26.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.63 Mn |
| Mar 31, 2026 | 25.53 Mn |
| Dec 31, 2025 | 28.57 Mn |
| Sep 30, 2025 | 35.21 Mn |
| Jun 30, 2025 | 23.90 Mn |
| Mar 31, 2025 | 29.28 Mn |
| Dec 31, 2024 | 37.96 Mn |
| Sep 30, 2024 | 47.11 Mn |
| Jun 30, 2024 | 35.16 Mn |
| Mar 31, 2024 | 36.40 Mn |
| Dec 31, 2023 | 47.67 Mn |
| Sep 30, 2023 | 102.59 Mn |
| Jun 30, 2023 | 75.30 Mn |
| Mar 31, 2023 | 51.17 Mn |
| Dec 31, 2022 | 54.15 Mn |
| Sep 30, 2022 | 88.19 Mn |
| Jun 30, 2022 | 101.63 Mn |
| Mar 31, 2022 | 87.54 Mn |
| Dec 31, 2021 | 86.06 Mn |
| Dec 31, 2020 | 51.51 Mn |